다발골수종 환자에서 보르테조밉(bortezomib) 투여 후 발생한 심부전 1예
Reversible Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
이 증례는 다발골수종으로 진단 후 보르테조밉, 멜팔란 및프레드니솔론 항암 치료를 시행 중 심부전이 악화되었던 사례이다. 심부전 악화 원인을 감별하기 위해 문진 및 혈액 검사를 시행했으나 특별한 소견은 없었다. 심독성이 보고된 보르테조밉이 그 원인일 가능성도 있다고 판단되어 보르테조밉 중단 및 보존적 치료 후 심부전이 호전되었다. 기존에 심장 질환이 있는 환자는 보르테조밉 투여 이후에 심장 질환이 악화될 수 있으므로 이에 유의해야 하겠다.
Abstract
Bortezomib (Velcade®) came into the spotlight as a target therapy for multiple myeloma. It acts through reversible inhibition ofintracellular proteasomes, which triggers apoptosis, with relative selectivity for malignant cells. It has been hypothesized that theaccumulation of damaged proteins in myocytes impairs cardiac function. Cardiotoxicity is a rare side effect of bortezomibtreatment. We report a case of reversible systolic heart failure that probably occurred after bortezomib treatment in a patient withmultiple myeloma. Patients being treated with bortezomib who have previously had cardiac comorbidities should undergo routinecardiac monitoring.
참고문헌 (10)
- Curran MP, "Bortezomib: a review of its use in patients with multiple myeloma", Drugs, 69, pp.859~888 (2009)
- Mearini G, "The ubiquitin-proteasome system in cardiac dysfunction", Biochim Biophys Acta, 1782, pp.749~763 (2008)
- Zolk O, "The ubiquitin-proteasome system: focus on the heart", Cardiovasc Res, 70, pp.410~421 (2006)
- Manickam P, "Bortezomib-induced dilated cardiomyopathy-myth or reality", E-Journal of Cardiology, 1, pp.40~44 (2011)
- Hacihanefioglu A, "Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib", Int J Hematol, 88, pp.219~222 (2008)
- Voortman J, "Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report", BMC Cancer, 6, pp.129~ (2006)
- Jerkins JH, "Bortezomib-induced severe congestive heart failure", Cardiology Research, 1, pp.20~23 (2010)
- Powell SR, "The ubiquitin-proteasome system in cardiac physiology and pathology", Am J Physiol Heart Circ Physiol, 291, pp.H1~H19 (2006)
- Enrico O, "Unexpected cardiotoxicity in haematological bortezomib treated patients", Br J Haematol, 138, pp.396~397 (2007)
- Richardson PG, "Bortezomib or high-dose dexamethasone for relapsed multiple myeloma", N Engl J Med, 352, pp.2487~2498 (2005)